Tracon Pharmaceuticals Company Profile (NASDAQ:TCON)

Analyst Ratings

Consensus Ratings for Tracon Pharmaceuticals (NASDAQ:TCON) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (346.25% upside)

Analysts' Ratings History for Tracon Pharmaceuticals (NASDAQ:TCON)
Show:
DateFirmActionRatingPrice TargetActions
2/1/2016Oppenheimer Holdings Inc.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2015Stifel NicolausBoost Price TargetBuy$16.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2015Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2015Needham & Company LLCInitiated CoverageBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Tracon Pharmaceuticals (NASDAQ:TCON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/11/2016Q1($0.70)($0.54)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q4($0.62)($0.91)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q3($0.51)($0.53)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.42)($0.24)$4.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q1($0.37)($0.50)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tracon Pharmaceuticals (NASDAQ:TCON)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.56)($0.56)($0.56)
Q2 20162($0.70)($0.46)($0.58)
Q3 20162($0.75)($0.48)($0.62)
Q4 20162($0.85)($0.50)($0.68)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tracon Pharmaceuticals (NASDAQ:TCON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tracon Pharmaceuticals (NASDAQ:TCON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/3/2016Ronald L ShazerInsiderSell1,003$7.48$7,502.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell1,500$9.90$14,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Jafco Super V3 Investment LimiMajor ShareholderSell5,300$10.16$53,848.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2015Jafco Super V3 Investment Limimajor shareholderSell3,168$10.01$31,711.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2015Jafco Super V3 Investment Limimajor shareholderSell1,448$10.01$14,494.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2015Jafco Super V3 Investment Limimajor shareholderSell21,920$10.10$221,392.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Jafco Super V3 Investment Limimajor shareholderSell15,100$10.08$152,208.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Jafco Super V3 Investment LimiMajor ShareholderSell7,600$12.13$92,188.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Jafco Super V3 Investment Limimajor shareholderSell22,303$12.99$289,715.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/22/2015Jafco Super V3 Investment Limimajor shareholderSell39,426$14.02$552,752.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Jafco Super V3 Investment Limimajor shareholderSell18,200$14.48$263,536.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Charles TheuerCEOSell10,000$17.34$173,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015H Casey LoganinsiderSell5,000$17.34$86,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Jafco Super V3 Investment Limimajor shareholderSell42,344$11.78$498,812.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Jafco Super V3 Investment Limimajor shareholderSell60,038$11.78$707,247.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Charles TheuerCEOSell3,516$12.00$42,192.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2015Jafco Super V3 Investment Limimajor shareholderSell12,000$10.71$128,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Jafco Super V3 Investment Limimajor shareholderSell5,700$10.47$59,679.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Jafco Super V3 Investment Limimajor shareholderSell6,600$10.48$69,168.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Jafco Super V3 Investment Limimajor shareholderSell15,300$10.51$160,803.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Jafco Super V3 Investment Limimajor shareholderSell14,000$10.42$145,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Jafco Super V3 Investment LimiMajor ShareholderSell3,000$11.00$33,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Jafco Super V3 Investment Limimajor shareholderSell10,683$11.36$121,358.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Jafco Super V3 Investment LimiMajor ShareholderSell11,174$11.71$130,847.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Jafco Super V3 Investment LimiMajor ShareholderSell9,361$11.60$108,587.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015M James BarrettMajor ShareholderBuy500,000$10.00$5,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tracon Pharmaceuticals (NASDAQ:TCON)
DateHeadline
07/23/16 10:31 AMIs $14 Price Target Attainable For TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)? - Investor Newswire
07/23/16 10:31 AMStock Up Nicely This Week: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - TGP
07/20/16 07:45 PMEquity Roundup: Stock Performance Focus on TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Press Telegraph
07/19/16 07:43 AMEarnings Focus and Crowd Sourced Sentiment Review for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - TGP
07/19/16 07:43 AMWere Analysts Bearish TRACON Pharmaceuticals Inc (NASDAQ:TCON) This Week? - Consumer Eagle
07/17/16 09:43 AMShares Moving Down on the Week: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Engelwood Daily
07/17/16 09:43 AMTRACON Pharmaceuticals, Inc. (TCON) Broker Price Targets For The Coming Week - Fiscal Standard
07/16/16 09:54 AMShares Experiencing a Downtrend: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - TGP
07/14/16 07:01 PMAnalyst Target and Average Rating Watch: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Press Telegraph
07/14/16 07:01 PMTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 07:01 PMStrong Sell Calls For TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) At 0 - Investor Newswire
07/12/16 11:04 AMTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 11:04 AMSession Volatility Review for: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Engelwood Daily
07/08/16 06:42 PMHeightened Volatility Check on: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Engelwood Daily
07/08/16 06:42 PMCompany Stock Focus for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON): Which Way Will Shares Head? - Press Telegraph
07/08/16 06:42 PMIs $26 Within Reach For TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)? - Investor Newswire
07/08/16 06:42 PMBroker Outlook For TRACON Pharmaceuticals, Inc. (TCON) - Fiscal Standard
07/06/16 07:10 PMIncreased Volatility Watch for: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Engelwood Daily
07/06/16 07:10 PMTRACON Pharmaceuticals Inc (NASDAQ:TCON)'s Company Shares Decreased 43.53% After High Volatility - Engelwood Daily
07/05/16 06:23 PMBroker Outlook For The Week Ahead TRACON Pharmaceuticals, Inc. (TCON) - Fiscal Standard
07/05/16 06:23 PMShares Touching a Recent Low: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Press Telegraph
07/03/16 09:19 AMAre Analysts Bullish TRACON Pharmaceuticals Inc (NASDAQ:TCON) After Last Week? - Press Telegraph
06/30/16 06:54 PMTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Earnings Glance and Target Price Review - Engelwood Daily
06/29/16 09:29 AMStock Volatility in Review: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Engelwood Daily
06/27/16 09:20 AMNext Weeks Broker Price Targets For TRACON Pharmaceuticals, Inc. (TCON) - Fiscal Standard
06/23/16 07:28 PMStrong Sell Calls Recommendations For TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) At 0 - Investor Newswire
06/17/16 09:24 AMStrong Buy Calls Count For TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) At 3 - Investor Newswire
06/17/16 09:24 AMTRACON Pharmaceuticals, Inc. (TCON) Current Analyst Ratings - Fiscal Standard
06/16/16 11:12 AMStock Runners: Asanko Gold Inc. (NYSEMKT:AKG), TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), Navistar ... - KC Register
06/07/16 06:01 AMTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/06/16 07:28 AMTRACON Pharmaceuticals Announces Positive Results from TRC105 and TRC102 Clinical Trials at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting - [at noodls] - Median PFS greater than 12 months with continued durable complete responses observed in angiosarcoma patients treated with TRC105 and Votrient® in Phase 1b/2 trial Partial responses seen in solid tumor ...
06/06/16 07:10 AM8:10 am Tracon Pharmaceuticals announces 'Positive' Results from TRC105 and TRC102 Clinical Trials at ASCO; Median PFS greater than 12 months with continued durable complete responses observed in angiosarcoma patients treated with TRC105 an -
06/03/16 07:25 PMStock Review and Earnings Check on TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - HNN
06/03/16 03:03 PMTRACON PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/02/16 07:13 PMTarget Price and Stock Performance Rundown for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - HNN - Target Price and Stock Performance Rundown for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)HNNDuring the latest trading session, TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) shares traded +2.93%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/02/16 07:13 PMTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Stock Update & Estimates - Stock Tick Tock - TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to post earnings of $-0.64 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
05/31/16 03:23 PMTRACON Pharmaceuticals to Present at Upcoming Investment Conferences - [at noodls] - SAN DIEGO, May 31, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics ...
05/31/16 10:19 AMVersar Inc. (NYSEMKT:VSR) rose 7.76%: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), Nautilus Inc. (NYSE:NLS ... - KC Register - Versar Inc. (NYSEMKT:VSR) rose 7.76%: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), Nautilus Inc. (NYSE:NLS ...KC RegisterVersar Inc. (NYSEMKT:VSR) reported that, Revenue for the third quarter of fiscal year 2016 decreased 8% to $36.5 million, compared to revenues of $39.8 million during the third quarter of last fiscal year. Gross margin decreased to 4%, compared to 8 ...
05/30/16 10:42 PMPerformance at a Glance on TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - HNN - Performance at a Glance on TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)'s stock has performed at various points in its past ...and more »
05/30/16 10:42 PMAfter Last Week What Do Analysts Think Of TRACON Pharmaceuticals, Inc. (TCON) - Share Trading News - After Last Week What Do Analysts Think Of TRACON Pharmaceuticals, Inc. (TCON)Share Trading NewsThe share price of TRACON Pharmaceuticals, Inc. (TCON) was down -0.61% during the last trading session, with a day high of 6.57. 51474 shares were traded on TRACON Pharmaceuticals, Inc.'s last session. The stock's 50 day moving average is 7.08 and ...Tracon Pharmaceuticals Incorporated (NASDAQ:TCON) Shorts Decreased by 12.63% After Short CoveringFranklin Independentall 3 news articles »
05/27/16 11:46 AMEarnings Review and Stock Rundown for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) - Wall Street Hints and News - Earnings Review and Stock Rundown for TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting TRACON Pharmaceuticals, Inc.and more »
05/26/16 10:50 AMTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Quarterly EPS From Continuing Operations Stands At $-0.5358 - Stocks Daily - TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Quarterly EPS From Continuing Operations Stands At $-0.5358Stocks DailyFor the year ended 2016-03-31 TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) basic consolidated EPS reported was $-2.1959. For the quarter ended 2016-03-31, it came at $-2.1959. EPS is a part of a firm's earnings that is owed to each outstanding stock.
05/26/16 10:50 AMLatest Analyst Ratings For TRACON Pharmaceuticals, Inc. (TCON) - Share Trading News - Latest Analyst Ratings For TRACON Pharmaceuticals, Inc. (TCON)Share Trading NewsTRACON Pharmaceuticals, Inc. has a 50 day moving average of 7.11 and a 200 day moving average of 7.91. The stock's market capitalization is 79.27M, it has a 52-week low of 5.88 and a 52-week high of 18.35. The share price of the company (TCON) was ...Tracon Pharmaceuticals Incorporated (NASDAQ:TCON) Shorted Shares Decreased By 7.52%The Postall 2 news articles »
05/20/16 03:23 PMTRACON Pharmaceuticals Reports Granting of Inducement Award - [at noodls] - SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics ...
05/18/16 03:32 PMTRACON Pharmaceuticals Initiates Dosing in Phase 1b/2 Study of TRC105 in Patients with Hepatocellular Carcinoma - [at noodls] - SAN DIEGO, May 18, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics ...
05/17/16 12:32 PMTRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 03:32 PMTRACON Pharmaceuticals to Present at the UBS Global Healthcare Conference - [at noodls] - SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics ...
05/13/16 08:34 AMEdited Transcript of TCON earnings conference call or presentation 11-May-16 8:30pm GMT -
05/11/16 04:07 PMTRACON Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - SAN DIEGO, May 11, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics ...
05/11/16 04:06 PMTracon reports 1Q loss -

Social

About Tracon Pharmaceuticals

Tracon Pharmaceuticals logoTRACON Pharmaceuticals, Inc. (TRACON) is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, age-related macular degeneration (AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company's lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. Its other anti-endoglin antibody is TRC205, which is in preclinical development for the treatment of fibrotic diseases. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TCON
  • CUSIP:
Key Metrics:
  • Previous Close: $4.93
  • 50 Day Moving Average: $5.24
  • 200 Day Moving Average: $6.62
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $60.16M
  • Beta: 2.82
  • Current Year EPS Consensus Estimate: $-2.46 EPS
  • Next Year EPS Consensus Estimate: $-2.52 EPS
Additional Links:
Tracon Pharmaceuticals (NASDAQ:TCON) Chart for Saturday, July, 23, 2016